Non-small cell lung cancer (NSCLC) is now described as an extremely heterogeneous disease in its clinical presentation, histology, molecular characteristics, and patient conditions. Over the past 20 years, the management of lung cancer has evolved with positive results. Immune checkpoint inhibitors have revolutionized the treatment landscape for NSCLC in both metastatic and locally advanced stages. The identification of molecular alterations in NSCLC has also allowed the development of targeted therapies, which provide better outcomes than chemotherapy in selected patients. However, patients usually develop acquired resistance to these treatments. On the other hand, thoracic surgery has progressed thanks to minimally invasive procedures, pre-habilitation and enhanced recovery after surgery. Moreover, within thoracic surgery, precision surgery considers the patient and his/her disease in their entirety to offer the best oncologic strategy. Surgeons support patients from pre-operative rehabilitation to surgery and beyond. They are involved in post-treatment follow-up and lung cancer recurrence. When conventional therapies are no longer effective, salvage surgery can be performed on selected patients.
非小细胞肺癌（NSCLC）目前被认为在临床表现、组织学特征、分子特性和患者状况方面具有高度异质性。过去二十年间，肺癌的治疗管理取得了积极进展。免疫检查点抑制剂彻底改变了转移性和局部晚期非小细胞肺癌的治疗格局。非小细胞肺癌分子变异的识别也推动了靶向疗法的发展，为特定患者提供了优于化疗的疗效。然而，患者通常会对这些治疗产生获得性耐药。另一方面，胸外科手术因微创技术、术前预康复及术后加速康复理念而持续进步。此外，在胸外科领域，精准手术全面考量患者整体状况及其疾病特征，以制定最优肿瘤治疗策略。外科医生从术前康复到手术乃至术后全程支持患者，参与治疗后随访及肺癌复发管理。当常规疗法不再有效时，可对符合条件的患者实施挽救性手术。
肿瘤(癌症)患者之家